Why Nxstage Medical, Inc. Slumped Today

By Brian OrelliMarketsFool.com

What happened

Continue Reading Below

NxStage Medical (NASDAQ: NXTM) closed down 10.8% on no obvious news.

So what

The kidney-dialysis expert was trading at all-time highs yesterday, so it appears investors may be getting a little jittery with NxStage Medical scheduled to report first-quarter earnings next Tuesday. Even with today's drop, shares in the company are still up more than 60% over the last year.

More From Fool.com

Management expects NxStage Medical's business to pick up as the year progresses. Revenue guidance for the year is in the range of $400 million to $405 million, but management expects less than a quarter of that -- between $95 million and $97 million -- will hit the books in the first quarter. For earnings, a loss of $1 million to $3 million is expected in the first quarter, but management anticipates the rest of the year to wipe that out, with positive earnings for 2017 in its entirety.

Image source: Getty Images.

Now what

Long-term investors can ignore random movements -- in both directions -- that don't seem to have any reason behind them.

Beyond earnings next week, investors should be on the lookout for an approval by the U.S. Food and Drug Administration for NxStage's next-generation hemodialysis system, System One. In March, the company gained CE Marking approval for the system, allowing it to be sold in the EU.

10 stocks we like better than NxStage MedicalWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and NxStage Medical wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 1, 2017

Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends NxStage Medical. The Motley Fool has a disclosure policy.